Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir

Posted on June 10, 2016 by Christoph Sarrazin, Hadas Dvory-Sobol, Evguenia S. Svarovskaia, Brian Doehle, Phillip S. Pang, Shu-Min Chuang, Julie Ma, Xiao Ding, Nezam H. Afdhal, Kris V. Kowdley, Edward J. Gane, Eric Lawitz, Diana M. Brainard, John G. McHutchison, Michael D. Mill

We evaluated the effects of baseline hepatitis C virus (HCV) NS5A, NS5B, and NS3 resistance-associated substitutions (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection.

This entry was posted in News. Bookmark the permalink.